Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
RUBRAMIN PC is an injectable small-molecule product approved in 1950 by Bristol Myers Squibb. The specific indication and mechanism of action are not publicly documented in available data; however, the brand's 70+ year history and injectable route suggest a legacy therapeutic agent. This product represents a mature, established treatment in its therapeutic class.
Loss of exclusivity is approaching; the brand team is likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on RUBRAMIN PC offers limited upside for career growth given the approaching LOE and zero linked job openings. Roles available are typically operational (supply chain, regulatory) focused on portfolio defense rather than commercial expansion or innovation.
Worked on RUBRAMIN PC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.